UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K _____________________________________________________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2025 _____________________________________________________________ D-Wave Quantum Inc. (Exact Name of Registrant as Specified in Its Charter) _____________________________________________________________ Delaware 001-4146 ...

Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | January 2025 Forward-Looking Statements This communication includes express and implied "forward-looking statements," including forward-looking statements within the meaning of the Private Securities Littleation Reforical frances naticals oncernes include all statements that are not thistorical facts and, in same cases can be identified op terms such as may Reforio for 1995. Forw "will " "ongoing," or the negative of these ter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Québec 001-39335 Not applicable (I.R.S. Employer Identification No.) Registrant's Telephone Number, Including Area Code: (857) 412-7018 Date of Report (Date of earliest event reported): January 9, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) 7171 Frederick-B ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusett ...

Exhibit 99.1 Neogen Announces Preliminary 1 Second-Quarter 2025 Results 1 Results presented in this release are preliminary and unaudited estimates based on information currently available to the Company. Such results could differ from the final amounts the Company reports in its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2024. The Company assumes no obligation, and does not intend, to update these estimates prior to filing its Form 10-Q. 2 Non-GAAP financial measures; see expla ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Date of Report (Date of earliest event reported): January 8, 2025 PASSAGE BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39231 82-2729751 (State or other jurisdiction of incorporation) One Commerce Square 2005 Market Street, 39 Floor Philadelphia, PA 19103 (Address of principal executive offices) (Zip Code) (Commission File Number) (IRS Employer Identification No.) (267) 866-0311 FORM 8-K CURRENT REPORT Pu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 101 Cambridgepark Drive Cambridge, MA 02140 (Address of princip ...

EXHIBIT 99.1 Tilray Brands Reports Q2 2025 Financial Results Gross Profit Increased by 29% Year-Over-Year, Reaching $61 Million in Q2 with Growth Across All Four Business Segments Achieved 9% Year-Over-Year Growth, Generating Record Q2 Net Revenue of $211 Million, 10% in Constant Currency Beverage Revenue Increase by 36%, International Cannabis by 25%, Wellness Segment by 13% Announces Project 420: A $25 Million Synergy Plan for Tilray Beverage Business Tilray Reaffirms Fiscal Year 2025 Guidance Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025 Dyne Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39509 36-4883909 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1560 Trapelo Road Waltham, Massachusetts 02451 (Address of Principa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 ASTRONICS CORPORATION (Exact name of registrant as specified in its charter) New York 0-7087 16-0959303 (State of Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 130 Commerce Way East Aurora, New York 14052 (Address of principa ...